Triple receptor agonist (GLP-1 + GIP + glucagon)
GLP-3 (RET)
Triple receptor agonist (GLP-1 + GIP + glucagon) for advanced metabolic research.
- Half-life~6 days, once-weekly dosing
- Dose rangeTitrate from 2 mg/wk to 12 mg/wk over 24 weeks
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Activates all three incretin and glucagon pathways. The glucagon arm contributes additional energy expenditure and lipid mobilisation beyond the GLP-1/GIP effects.
Research
What the research shows.
Phase 3 trial data shows ~24% body weight reduction at 48 weeks at the 12 mg dose, the largest effect in the GLP-class family. Steeper titration curve required.
GLP-3 (RET) is the codename for a triple receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The newest of the three GLP-class research lines and the one with the largest absolute effect in published trial data.
The trade-off is more aggressive titration requirements and a slightly higher rate of GI side effects compared with the single-receptor and dual-receptor lines. Research-grade only at NuroCore; licensed-medicine versions exist in a different regulatory category.
Contraindications
When not to use.
Personal/family history of medullary thyroid carcinoma or MEN-2. Active pancreatitis. Pregnancy. Severe renal or hepatic impairment.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.